Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $47.50 | Overweight | Morgan Stanley |
| 8/10/2023 | $70.00 | Overweight | Cantor Fitzgerald |
| 3/2/2022 | $194.00 → $102.00 | Outperform | SVB Leerink |
| 1/21/2022 | $64.00 | Outperform | Macquarie |
| 12/15/2021 | $189.00 → $136.00 | Overweight | JP Morgan |
| 11/11/2021 | $222.00 → $217.00 | Buy | Citigroup |
| 11/10/2021 | $200.00 → $194.00 | Outperform | SVB Leerink |
| 10/12/2021 | Market Perform | Bernstein |
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. "There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefin
Improved overall survival (OS), progression-free survival (PFS) and confirmed objective response rate (ORR) were observed in the China subpopulation treated with TIVDAK compared to chemotherapy, consistent with those in the global population The safety profile of TIVDAK among the China subpopulation was manageable and consistent with that observed in the global population Zai Lab intends to submit a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) in the first quarter of 2025 Zai Lab will leverage its commercial footprint of ZEJULA in women's cancer to bring the medicine to patients in China if approved Zai Lab Limited (NASDAQ:ZLAB, HKEX: 96
- Exclusive collaboration and licensing agreement for povetacicept in the region - - Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activatin
8-K - Zai Lab Ltd (0001704292) (Filer)
144 - Zai Lab Ltd (0001704292) (Subject)
8-K - Zai Lab Ltd (0001704292) (Filer)
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt
SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog
Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50
Cantor Fitzgerald initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $70.00
SVB Leerink reiterated coverage of Zai Lab with a rating of Outperform and set a new price target of $102.00 from $194.00 previously
Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected regulatory submission in early 2025 Global Phase 1 data of ZL-1310 (DLL3 ADC) suggests best-in-class potential in extensive-stage SCLC Three product launches in mainland China expected by the end of 2024, and up to four potential regulatory submissions to the NMPA in the next six months Strong balance sheet with a cash position1 of $716.1 million as of September 30, 2024, compared to $730.0 million as of June 30, 2024 Conference call and webcast today, November 12, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab L
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)
Company to host conference call and webcast on October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following plenary oral presentation of data at the EORTC-NCI-AACR Symposium (ENA) 2024 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Compan
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
SC 13G - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)